SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
Malaria treatment: Halofantrine
Read more from SRI
-
SRI to be presented with three IEEE Milestones for innovations that have transformed our lives
The Milestones honor PARC’s invention of the Alto personal computer, Ethernet, and the Laser Printer.
-
SRI works with N4 Pharma to target and treat cells in the human body that had been unreachable
Paving the way for targeted treatments, the collaboration aims to help realize the full potential of precision healthcare.
-
Researchers aim to disrupt how new materials are leveraged in the design process
SRI chosen by DARPA to develop next-generation computational design of metallic parts and intelligent testing of alloys.